Affiliation:
1. Thoracic Surgery Department The Fourth Medical Center of PLA General Hospital Beijing China
2. Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
3. Department of Oncology Shanghai Medical College, Fudan University Shanghai China
4. Shanghai Clinical Research Center for Radiation Oncology Shanghai Key Laboratory of Radiation Oncology Shanghai China
5. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
6. Department of Medical Oncology Sanhuan Cancer Hospital of Chaoyang District Beijing China
7. Department of Interventional Treatment Tianjin Medical University Cancer Hospital and Institute Tianjin China
Abstract
AbstractPurposeMETis a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two,METfusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizingMETfusions in a large, real‐world Chinese cancer population.MethodsWe retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021.METfusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization.ResultsWe screened 79,803 patients across 27 tumor types and detected 155 putativeMETfusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority ofMET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, withST7,HLA‐DRB1, andKIF5Bas the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence ofTP53inMET+ alterations,EGFRL858R,EGFRL861Q, andMETamplification.ConclusionTo our knowledge, this is currently the largest study in characterizingMETfusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues forMET+ cancer patients.
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献